Hall Capital Management Co. Inc. Invests $461,000 in The Clorox Company (NYSE:CLX)

Hall Capital Management Co. Inc. acquired a new stake in shares of The Clorox Company (NYSE:CLX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,836 shares of the company's stock, valued at approximately $461,000.

Other hedge funds also recently made changes to their positions in the company. Integral Investment Advisors Inc. grew its holdings in Clorox by 4.1% in the 4th quarter. Integral Investment Advisors Inc. now owns 1,718 shares of the company's stock worth $279,000 after acquiring an additional 67 shares during the last quarter. Sound View Wealth Advisors Group LLC grew its stake in shares of Clorox by 6.1% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,345 shares of the company's stock worth $218,000 after purchasing an additional 77 shares during the last quarter. Wedbush Securities Inc. grew its stake in shares of Clorox by 1.2% in the fourth quarter. Wedbush Securities Inc. now owns 7,624 shares of the company's stock worth $1,238,000 after purchasing an additional 94 shares during the last quarter. Global X Japan Co. Ltd. increased its holdings in Clorox by 3.0% during the 4th quarter. Global X Japan Co. Ltd. now owns 3,272 shares of the company's stock valued at $531,000 after purchasing an additional 95 shares during the period. Finally, Aviance Capital Partners LLC raised its position in Clorox by 3.2% during the 4th quarter. Aviance Capital Partners LLC now owns 3,180 shares of the company's stock valued at $516,000 after purchasing an additional 100 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Clorox

In other news, Director Pierre R. Breber bought 4,000 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was acquired at an average cost of $136.57 per share, with a total value of $546,280.00. Following the completion of the acquisition, the director now owns 4,000 shares of the company's stock, valued at approximately $546,280. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.57% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Evercore ISI set a $140.00 price objective on Clorox and gave the stock an "underperform" rating in a research report on Tuesday, May 6th. Barclays cut their price target on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a report on Wednesday, May 7th. UBS Group decreased their price objective on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. JPMorgan Chase & Co. cut their target price on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Finally, Morgan Stanley lowered their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Clorox presently has an average rating of "Hold" and a consensus price target of $151.23.

Clorox Stock Down 0.4%

Shares of Clorox stock traded down $0.58 during midday trading on Tuesday, hitting $130.30. The company had a trading volume of 2,190,099 shares, compared to its average volume of 1,337,366. The Clorox Company has a 52-week low of $127.60 and a 52-week high of $171.37. The company has a debt-to-equity ratio of 20.52, a quick ratio of 0.60 and a current ratio of 0.94. The stock has a market capitalization of $16.06 billion, a P/E ratio of 35.60, a P/E/G ratio of 2.62 and a beta of 0.60. The company has a 50 day moving average of $139.05 and a 200 day moving average of $151.85.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The company had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same period last year, the firm posted $1.71 earnings per share. The company's revenue was down 8.0% compared to the same quarter last year. On average, equities analysts predict that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.